https://doi.org/10.4081/ejh.2022.3561
SerpinB3 administration protects liver against ischemia-reperfusion injury
Submitted: 21 September 2022
Accepted: 12 October 2022
Published: 28 October 2022
Accepted: 12 October 2022
Abstract Views: 722
PDF: 501
HTML: 29
HTML: 29
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
We have investigated the change in SerpinB3 during hepatic ischemia and the potential role of its antiprotease activity in cell protection by the administration of wild-type SerpinB3 (SerpinB3-WT) or active loop-deleted recombinant SerpinB3 protein (SerpinB3-D) in a rat model of ischemia (60 min)/reperfusion (60 min) (I/R). A time-dependent increase of SerpinB3, both at transcription and protein level, was found in ischemic livers after 60, 120 and 180 min. SerpinB3-WT decreased polymorphonuclear cell infiltration and serum enzymes and increased ATP when compared with I/R group. These events were not obtained using SerpinB3-D. No significant changes in both liver SerpinB3 mRNA and protein were found in all I/R groups considered. The present data show that the administration of SerpinB3-WT reduced the I/R injury and this effect appears to be dependent on its anti-protease activity.
Li J, Li RJ, Lv GY, Liu HQ. The mechanisms and strategies to protect from hepatic ischemia-reperfusion injury. Eur Rev Med Pharmacol Sci 2015;19:2036–47.
Camargo CA, Madden JF, Gao W, Selvan RS, Clavien PA. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 1997;26:1513–20.
DOI: https://doi.org/10.1002/hep.510260619
Gracia-Sancho J, Casillas-Ramírez A, Peralta C. Molecular pathways in protecting the liver from ischaemia/reperfusion injury: a 2015 update. Clin Sci (Lond) 2015;129:345–62.
DOI: https://doi.org/10.1042/CS20150223
Ye L, He S, Mao X, Zhang Y, Cai Y, Li S. Effect of hepatic macrophage polarization and apoptosis on liver ischemia and reperfusion injury during liver transplantation. Front Immunol 2020;11:1193.
DOI: https://doi.org/10.3389/fimmu.2020.01193
Ciscato F, Sciacovelli M, Villano G, Turato C, Bernardi P, Rasola A, et al. SERPINB3 protects from oxidative damage by chemotherapeutics through inhibition of mitochondrial respiratory complex I. Oncotarget 2014;5:2418–27.
DOI: https://doi.org/10.18632/oncotarget.1411
Cannito S, Turato C, Paternostro C, Biasiolo A, Colombatto S, Cambieri I, et al. Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells. Oncotarget 2015;6:2206–21.
DOI: https://doi.org/10.18632/oncotarget.2943
Quarta S, Vidalino L, Turato C, Ruvoletto M, Calabrese F, Valente M, et al. SERPINB3 induces epithelial - Mesenchymal transition. J Pathol 2010;221:343–56.
DOI: https://doi.org/10.1002/path.2708
Sheshadri N, Catanzaro JM, Bott AJ, Sun Y, Ullman E, Chen EI, et al. SCCA1/SERPINB3 promotes oncogenesis and epithelial-mesenchymal transition via the unfolded protein response and IL6 signaling. Cancer Res 2014;74:6318-29.
DOI: https://doi.org/10.1158/0008-5472.CAN-14-0798
Correnti M, Cappon A, Pastore M, Piombanti B, Lori G, Oliveira DVPN, et al. The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma. Liver Int 2022;42:233–48.
DOI: https://doi.org/10.1111/liv.15049
Turato C, Calabrese F, Biasiolo A, Quarta S, Ruvoletto M, Tono N, et al. SERPINB3 modulates TGF-beta expression in chronic liver disease. Lab Invest 2010;90:1016–23.
DOI: https://doi.org/10.1038/labinvest.2010.55
Turato C, Biasiolo A, Pengo P, Frecer V, Quarta S, Fasolato S, et al. Increased antiprotease activity of the SERPINB3 polymorphic variant SCCA-PD. Exp Biol Med (Maywood) 2011;236:281-90.
DOI: https://doi.org/10.1258/ebm.2011.010229
Ferrigno A, Pasqua LG Di, Berardo C, Siciliano V, Richelmi P, Vairetti M. Oxygen tension-independent protection against hypoxic cell killing in rat liver by low sodium. Eur J Histochem 2017;61:2798.
DOI: https://doi.org/10.4081/ejh.2017.2798
Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19.
DOI: https://doi.org/10.1053/jhep.2003.50193
Turato C, Vitale A, Fasolato S, Ruvoletto M, Terrin L, Quarta S, et al. SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis. Br J Cancer 2014;110:2708–15.
DOI: https://doi.org/10.1038/bjc.2014.246
Di Pasqua LG, Berardo C, Rizzo V, Richelmi P, Croce AC, Vairetti M, et al. MCD diet-induced steatohepatitis is associated with alterations in asymmetric dimethylarginine (ADMA) and its transporters. Mol Cell Biochem 2016;419:147-55.
DOI: https://doi.org/10.1007/s11010-016-2758-2
Hirao H, Dery KJ, Kageyama S, Nakamura K, Kupiec-Weglinski JW. Heme Oxygenase-1 in liver transplant ischemia-reperfusion injury: From bench-to-bedside. Free Radic Biol Med 2020;157:75-82.
DOI: https://doi.org/10.1016/j.freeradbiomed.2020.02.012
Aydin A, Sakrak O, Yilmaz TU, Kerem M. The effects of Hypericum perforatum on hepatic ischemia-reperfusion injury in rats. Bratisl Lek Listy 2014;115:209–15.
DOI: https://doi.org/10.4149/BLL_2014_049
Serracino-Inglott F, Habib NA, Mathie RT. Hepatic ischemia-reperfusion injury. Am J Surg 2001;181:160-6.
DOI: https://doi.org/10.1016/S0002-9610(00)00573-0
Jiménez-Castro MB, Cornide-Petronio ME, Gracia-Sancho J, Peralta C. Inflammasome-mediated inflammation in liver ischemia-reperfusion injury. Cells 2019;8:1131.
DOI: https://doi.org/10.3390/cells8101131
Kamo N, Ke B, Ghaffari AA, Shen X da, Busuttil RW, Cheng G, et al. ASC/caspase-1/IL-1β signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia/reperfusion injury. Hepatology 2013;58:351–62.
DOI: https://doi.org/10.1002/hep.26320
Ben-Ari Z, Issan Y, Katz Y, Sultan M, Safran M, Michal LS, et al. Induction of heme oxygenase-1 protects mouse liver from apoptotic ischemia/reperfusion injury. Apoptosis 2013;18:547–55.
DOI: https://doi.org/10.1007/s10495-013-0814-x
Gao RY, Wang M, Liu Q, Feng D, Wen Y, Xia Y, et al. Hypoxia-inducible factor-2α reprograms liver macrophages to protect against acute liver injury through the production of interleukin-6. Hepatology 2020;71:2105–17.
DOI: https://doi.org/10.1002/hep.30954
Lehwald N, Tao GZ, Jang KY, et al. Wnt-β-catenin signaling protects against hepatic ischemia and reperfusion injury in mice. Gastroenterology 2011;141:707-18.
DOI: https://doi.org/10.1053/j.gastro.2011.04.051
Terrin L, Agostini M, Ruvoletto M, et al. SerpinB3 upregulates the Cyclooxygenase-2/β-Catenin positive loop in colorectal cancer. Oncotarget 2017;8:15732-43.
DOI: https://doi.org/10.18632/oncotarget.14997
Cannito S, Foglia B, Villano G, et al. SerpinB3 differently up-regulates hypoxia inducible factors -1α and -2α in hepatocellular carcinoma: Mechanisms revealing novel potential therapeutic targets. Cancers (Basel) 2019;11:1933.
DOI: https://doi.org/10.3390/cancers11121933
Ogura J, Terada Y, Tsujimoto T, Koizumi T, Kuwayama K, Maruyama H, et al. The decrease in farnesoid X receptor, pregnane X receptor and constitutive androstane receptor in the liver after intestinal ischemia-reperfusion. J Pharm Pharm Sci 2012;15:616–31.
DOI: https://doi.org/10.18433/J38C88
Wanner GA, Ertel W, Müller P, Höfer Y, Leiderer R, Menger MD, et al. Liver ischemia and reperfusion induces a systemic inflammatory response through Kupffer cell activation. Shock 1996;5:34–40.
DOI: https://doi.org/10.1097/00024382-199601000-00008
Ratcliffe PJ. HIF-1 and HIF-2: working alone or together in hypoxia? J Clin Invest 2007;117:862-5.
DOI: https://doi.org/10.1172/JCI31750
Saidi RF, Kenari SKH. Liver ischemia/reperfusion injury: an overview. J Invest Surg 2014;27:366–79.
DOI: https://doi.org/10.3109/08941939.2014.932473
Selzner N, Selzner M, Jochum W, Clavien PA. Ischemic preconditioning protects the steatotic mouse liver against reperfusion injury: an ATP dependent mechanism. J Hepatol 2003;39:55–61.
DOI: https://doi.org/10.1016/S0168-8278(03)00147-8
Moon KH, Hood BL, Mukhopadhyay P, Rajesh M, Abdelmegeed MA, Kwon Y Il, et al. Oxidative inactivation of key mitochondrial proteins leads to dysfunction and injury in hepatic ischemia reperfusion. Gastroenterology 2008;135:1344–57.
DOI: https://doi.org/10.1053/j.gastro.2008.06.048
Liu J, Zhang W, Zhou C, Li M, Wang X, Zhang W, et al. Precision Navigation of hepatic ischemia–reperfusion injury guided by lysosomal viscosity-activatable NIR-II fluorescence. Am Chem Soc 2022;144:13586-99.
DOI: https://doi.org/10.1021/jacs.2c03832
Sun Y, Sheshadri N, Zong W. SERPINB3 and B4: From biochemistry to biology. Semin Cell Dev Biol 2017;62:170-7.
DOI: https://doi.org/10.1016/j.semcdb.2016.09.005
Lauko A, Volovetz J, Turaga SM, Bayik D, Silver JK, Mitchell K, et al. SerpinB3 drives cancer stem cell survival in glioblastoma. Cell Rep 2022;40:111348.
DOI: https://doi.org/10.1016/j.celrep.2022.111348
Ethics Approval
The use and care of animals in this experimental study was approved by the Italian Ministry of Health and by the University Commission for Animal Care: Protocol N° 533/2020 and Protocol N° 274/2021How to Cite
Turato, C., Vairetti, M., Cagna, M., Biasiolo, A., Ferrigno, A., Quarta, S., Ruvoletto, M., De Siervi, S., Pontisso, P., & Di Pasqua, L. G. (2022). SerpinB3 administration protects liver against ischemia-reperfusion injury. European Journal of Histochemistry, 66(4). https://doi.org/10.4081/ejh.2022.3561
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
